GlobalData on MSN3mon
China NMPA approves MSD’s KEYTRUDA for stages of NSCLC
China National Medical Products Administration (NMPA) has approved MSD’s KEYTRUDA for use in conjunction with ...
pharmaphorum6d
MSD hits a hurdle with its LAG-3 programme
MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable (MSS ...
Clinical Trials Arena on MSN7d
BioCity and MSD to evaluate cancer treatment combination in Phase I/II trial
BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...
pharmaphorum5y
MSD’s Keytruda plus chemo backed by NICE for lung cancer
Merck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell lung cancer (NSCLC) as part of a regimen with chemotherapy, says NICE. Draft ...